Icon

Nerlynx - (40 mg; Tablets)

Neratinib Maleate Puma Biotech
40 mg; Tablets
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy
Yes
*** *********** ******* ** **** **, ****. ** ******** **, ****, **** ******* *** ’*** ****** *** ***. *********, **** *** *** *********** ** ******, *** ********** ** *** ’*** ****** **** ** ******** **, ****, *** *** ****** **** **** ** ********* ***********.
Nerlynx Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
****** ******* **** *** **** *** ******* **** *** **** *** **** *** **** *** **** *** **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** / ********* *** **, **** ******* ********* ******** ******* *** **** *** *** ****
  1. *** **, **** : * **** ** *** ***** *** ***** ** * *** *******.
  2. *** **, **** : ****** ******** **** ********* *** **** ** ****** *** * ******.
  3. *** **, **** : **** ********* ****** **** ****** '***.
  4. *** **, **** : **** ********* ********** **** ******. ** ****** ** ** * **********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.